Humanexa Signals API
Coming SoonThe Humanexa Signals API will deliver scored regulatory, clinical, competitive, and market intelligence — built for internal dashboards, research systems, investment workflows, and AI agents.
We are validating demand before launching a public API. Join the early access waitlist to help shape endpoints, data coverage, and rollout priorities.
REST · JSON · Scored intelligence · Enterprise-ready
GET /api/signals{
"signals": [
{
"id": "sig_8f2a1c",
"slug": "fda-accepts-nda-filing-oncology-asset",
"title": "FDA Accepts NDA Filing for Phase III Oncology Asset",
"summary": "Regulatory acceptance sets a PDUFA target and signals FDA alignment on the filing package ahead of a competitive readout window.",
"insightLine": "Regulatory path now de-risked relative to peer timelines.",
"domain": "regulatory",
"category": "regulatory",
"subcategory": "fda",
"publishedAt": "2026-06-12T14:30:00Z",
"updatedAt": "2026-06-12T14:30:00Z",
"priority": "high",
"tags": [
"FDA",
"NDA",
"Oncology"
],
"statusLabel": "Active",
"intelligence": {
"importanceScore": 87,
"recommendedAction": "Monitor PDUFA date and label negotiation signals.",
"impactDomain": "Regulatory & Commercial",
"affectedEntities": [
"Acme Bio",
"Competitor X"
],
"strategicSummary": "Acceptance compresses uncertainty on launch timing and may shift competitive positioning in the indication.",
"confidenceScore": 0.92
}
}
],
"pagination": {
"total": 142,
"page": 1,
"limit": 20
}
}Overview
Every planned endpoint returns structured records with strategic scoring — designed for teams that need decision-grade context at scale.
Structured intelligence across regulatory, clinical, competitive, and market developments.
Forward-looking event intelligence for planning and portfolio monitoring.
Humanexa scoring and strategic context on every record — not raw headlines.
Example Endpoints
These endpoints illustrate the schema and intelligence layer we are building. Availability will roll out to early access partners first.
/api/signalsLatest structured intelligence signals across all categories.
GET /api/signals{
"signals": [
{
"id": "sig_8f2a1c",
"slug": "fda-accepts-nda-filing-oncology-asset",
"title": "FDA Accepts NDA Filing for Phase III Oncology Asset",
"summary": "Regulatory acceptance sets a PDUFA target and signals FDA alignment on the filing package ahead of a competitive readout window.",
"insightLine": "Regulatory path now de-risked relative to peer timelines.",
"domain": "regulatory",
"category": "regulatory",
"subcategory": "fda",
"publishedAt": "2026-06-12T14:30:00Z",
"updatedAt": "2026-06-12T14:30:00Z",
"priority": "high",
"tags": [
"FDA",
"NDA",
"Oncology"
],
"statusLabel": "Active",
"intelligence": {
"importanceScore": 87,
"recommendedAction": "Monitor PDUFA date and label negotiation signals.",
"impactDomain": "Regulatory & Commercial",
"affectedEntities": [
"Acme Bio",
"Competitor X"
],
"strategicSummary": "Acceptance compresses uncertainty on launch timing and may shift competitive positioning in the indication.",
"confidenceScore": 0.92
}
}
],
"pagination": {
"total": 142,
"page": 1,
"limit": 20
}
}/api/signals?category=regulatoryFilter signals to a single intelligence category.
GET /api/signals?category=regulatory{
"signals": [
{
"id": "sig_3b9d44",
"slug": "ema-chmp-positive-opinion-rare-disease",
"title": "EMA CHMP Issues Positive Opinion for Rare Disease Therapy",
"domain": "regulatory",
"category": "regulatory",
"subcategory": "ema",
"intelligence": {
"importanceScore": 79,
"recommendedAction": "Track EC decision and HTA implications in EU5.",
"strategicSummary": "Positive CHMP opinion supports near-term EU access planning for a differentiated rare disease asset.",
"confidenceScore": 0.88
}
}
],
"pagination": {
"total": 38,
"page": 1,
"limit": 20
}
}/api/signals?subcategory=fdaDrill into subcategory-level regulatory coverage.
GET /api/signals?subcategory=fda{
"signals": [
{
"id": "sig_8f2a1c",
"slug": "fda-accepts-nda-filing-oncology-asset",
"title": "FDA Accepts NDA Filing for Phase III Oncology Asset",
"domain": "regulatory",
"category": "regulatory",
"subcategory": "fda",
"intelligence": {
"importanceScore": 87,
"recommendedAction": "Monitor PDUFA date and label negotiation signals.",
"strategicSummary": "Acceptance compresses uncertainty on launch timing and may shift competitive positioning.",
"confidenceScore": 0.92
}
}
],
"pagination": {
"total": 14,
"page": 1,
"limit": 20
}
}/api/catalystsUpcoming catalysts with priority scoring and strategic context.
GET /api/catalysts{
"catalysts": [
{
"id": "cat_91e0f3",
"title": "PDUFA Decision — Phase III Oncology Asset",
"company": "Acme Bio",
"asset": "ACB-401",
"category": "Oncology · Immunotherapy",
"signalScore": 91,
"recommendedAction": "Prepare scenario analysis for label breadth outcomes.",
"timeHorizon": "Q3 2026",
"priorityScore": 94,
"catalystSummary": "FDA action date for a registrational asset with direct competitive overlap in second-line settings.",
"publishedAt": "2026-06-10T09:00:00Z",
"eventCategory": "Regulatory Decision",
"intelligence": {
"importanceScore": 94,
"signalScore": 91,
"recommendedAction": "Model upside/downside on approval and label scope.",
"strategicSummary": "Decision window is a near-term valuation and positioning inflection for the company and peers.",
"impactDomain": "Regulatory & Investment"
}
}
],
"pagination": {
"total": 56
}
}Early Access
Join the waitlist for launch updates and priority access. For enterprise deployments, custom SLAs, or integration planning, contact our sales team directly.